LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics' First Quarter 2026 Financial Results Conference Call.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Dorset Management David M. Knott | 33,732 | $308,648 | -38% | 0.18% |
| 2. | Algert Coldiron Investors Peter Algert And Kevin Coldiron | 0 | $0 | 0% | |
| 3. | Propel Bio Management Leen Kawas And Richard Kayne | 0 | $0 | 0% | |
| 4. | Aster Capital Management (DIFC) Ltd Nabil Ouajjane | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.92 | 5,592 | $49,890.15 | 5,592 | 2026-03-27 | Filing | |
| $8.95 | 28,089 | $251,410.59 | 77,289 | 2026-03-27 | Filing | |
| $8.57 | 7,500 | $64,275.00 | 12,886 | 2026-03-27 | Filing | |
| $22.79 | 10,500 | $239,278.20 | 10,500 | 2025-11-07 | Filing | |
| $22.76 | 2,178 | $49,562.79 | 5,386 | 2025-11-07 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.37 | 5,788 | $152,611.62 | 4,733 | 2025-11-17 | Filing | |
| $25.74 | 4,212 | $108,410.56 | 10,521 | 2025-11-17 | Filing | |
| $47.01 | 123 | $5,782.64 | 764,127 | 2025-09-30 | Filing | |
| $47.01 | 177 | $8,321.35 | 1,050,599 | 2025-09-30 | Filing | |
| $46.41 | 57,502 | $2,668,483.81 | 764,250 | 2025-09-30 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,656,888 | $24,310,525 | 17.19% | |
| 2. | 1,976,823 | $18,087,931 | 0% | |
| 3. | 1,156,161 | $10,578,873 | 0.02% | |
| 4. | 1,100,148 | $10,066,354 | 0% | |
| 5. | 1,041,188 | $9,526,870 | 0% |